Organization

Entera Bio

Developer of EB613, an oral osteoporosis treatment under investigation.

Sources

Attribution and reporting linked by this record; links do not imply independent verification.

Welcome to October 10, 2026 (theinnermostloop.substack.com)
Source linked by the October 10 issue (www.globenewswire.com)

Developer of EB613, an oral osteoporosis treatment under investigation. This description follows the October 10 newsletter and its linked source.

Visit resource ↗

Development timeline

Newest reporting dates first. Reporting dates may differ from event dates.

2026-10-10: Entera Bio receives favorable feedback on an osteoporosis trial plan

Knowledge graphopen in browser →

Cite or correct this record

Citation formatCitation text

Entera Bio
Innermost Loop KB — secondary record
Reporting date: unknown
KB permalink: https://nicholsn.github.io/innermost-loop-kb/organizations/entera-bio
Attributed sources:
- Welcome to October 10, 2026 — https://theinnermostloop.substack.com/p/welcome-to-october-10-2026
- Source linked by the October 10 issue — https://www.globenewswire.com/news-release/2026/06/22/3315282/0/en/entera-bio-receives-positive-fda-feedback-on-12-month-registrational-phase-3-study-for-eb613-the-first-oral-anabolic-tablet-in-development-for-postmenopausal-women-with-osteoporosi.html
This citation does not imply independent verification of linked-source claims.

Suggest a correction — opens a GitHub draft for you to review and submit.